EPOCh

• Research type

  Research Study

• Full title

  A randomised, double-blind, placebo-controlled crossover study to assess the efficacy of a single dose of 100mg of VRP700 by inhalation in reducing the frequency and severity of cough in adult patients with Idiopathic Pulmonary Fibrosis

• IRAS ID

  122332

• Contact name

  Jaclyn Smith

• Sponsor organisation

  Verona Pharma plc

• Eudract number

  2012-005794-31

• Research summary

  People cough in order to clear their airways. Most coughs are caused by viruses and settle down by themselves, but some people develop persistent (or chronic) coughing which can last for many years, particularly if they have conditions like idiopathic pulmonary fibrosis (or IPF). People with chronic cough find the symptoms very troublesome and it can have a major impact on their quality of life. Our research aims to look at whether a research drug called VRP700 helps to reduce the amount a person coughs compared to placebo (a dummy drug). Cough is one of the most debilitating medical complaints reported by patients, especially in patients with respiratory problems such as asthma, chronic obstructive pulmonary disease (COPD), lung cancer, fibrosis or infection. However there remains no truly safe and effective treatment for cough since currently available treatments are either morphine based or derivatives of morphine, which have significant unwanted effects that limit the doses that can be administered and the use of such drugs.

• REC name

  North West - Greater Manchester South Research Ethics Committee

• REC reference

  13/NW/0054

• Date of REC Opinion

  18 Feb 2013

• REC opinion

  Favourable Opinion